Temozolomide and Bevacizumab in Treating Patients With Metastatic Melanoma of the Eye

NCT01217398 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Intraocular Melanoma

Interventions

BIOLOGICAL: bevacizumab
DRUG: temozolomide
GENETIC: polymorphism analysis
OTHER: pharmacogenomic studies

Sponsor

Institut Curie